ReviewChemical Society reviews2025
Bilayer nanographenes: structure, properties, and synthetic challenges.
Review in Chemical Society reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Dispersion-Clamped Crystalline Supramolecular Columnar π-Stacks of Adamantyl-Substituted Pyrenes.Angewandte Chemie (International ed. in English) · 2026Article
- Exact benzannulation regulates packing and circularly polarized luminescence in a chiral bilayer nanographene.Chemical science · 2026Article
- Topology and peripheral functionality govern intramolecular π-π stacking, solid-state self-assembly and chiroptical activity in rigid bilayer nanographenes.Chemical science · 2026Article
- A saddle-shaped OBO-doped nanographene: facile synthesis, adaptive double-layer assembly, and enhanced Lewis acidity.Chemical science · 2026Article
- Skeletal transformation to chiral nanocarbon molecules.Nature communications · 2026Article
- Nanographene-Based van der Waals Organic Framework With Permanent Porosity.Angewandte Chemie (International ed. in English) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molecular nanographenes (NGs)-graphene analogues at the nanoscale-exhibit atomically defined monodispersity in both size and shape. This synthetic precision enables fine control over their properties. Among the emerging strategies to modulate their electronic and optical properties, vertical π-π stacking between the graphitized layers has recently gained attention as a powerful design tool. In this review, we explore the synthesis, structural features, and functional implications of bilayer and multilayer nanographenes, with a particular focus on the bilayer effect-a through-space electronic communication arising from the interlayer overlap. We discuss how the degree of π-π overlap, rather than solely π-extension, governs key properties such as HOMO-LUMO gap, redox behavior, photoluminescence shifts and quatum yields, and chiroptical responses. Molecular architectures incorporating helicenes, spirocycles, or non-benzenoid motifs enable the deviation from planarity, ususally presented in nanographenes, allowing the precise synthesis of covalently π-π stacked topologies that amplify this effect. Furthermore, this concept also extends to other NGs such as multilayers, supramolecular assemblies, and donor-acceptor complexes, revealing the versatility of the bilayer approach. The first synthetic approaches to access enantiomerically pure bilayer NGs are also disclosed, opening new avenues for their use in advanced technological applications. Overall, the bilayer effect emerges as a novel structural parameter for tuning the properties and function of π-conjugated carbon-based materials, opening new frontiers in molecular chiral optoelectronics, spintronics, and quantum nanoscience.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.